Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma – the GlioCave study (NOA 17 – ARO 2016/3 – DKTK ROG trial)

BACKGROUND: Glioblastoma relapses in the vast majority of cases within 1 year. Maximum safe resection of the recurrent glioblastoma can be offered in some cases. Re-irradiation has been established for the treatment of recurrent glioblastoma, too. In both cases, adjuvant treatment, mostly using temo...

Descripción completa

Detalles Bibliográficos
Autores principales: Straube, Christoph, Scherb, Hagen, Gempt, Jens, Kirschke, Jan, Zimmer, Claus, Schmidt-Graf, Friederike, Meyer, Bernhard, Combs, Stephanie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753454/
https://www.ncbi.nlm.nih.gov/pubmed/29298660
http://dx.doi.org/10.1186/s12885-017-3928-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753454/
https://www.ncbi.nlm.nih.gov/pubmed/29298660
http://dx.doi.org/10.1186/s12885-017-3928-7

Ejemplares similares